Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pixantrone + Fludarabine + Rituximab in Indolent NHL
NCT00577161Phase 3Withdrawn
- Sponsor
- CTI BioPharma Corp.
- Start
- Sep 2007
- Primary completion
- Jul 2012
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of pixantrone in Indolent Non-Hodgkin Lymphoma (INHL), sponsored by CTI BioPharma Corp.. Planned start Sep 2007; status: withdrawn.
02
Drugs
pixantrone
03
Conditions
Indolent Non-Hodgkin Lymphoma (INHL)
Beyond the preview
Go deeper on NCT00577161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00577161.